Pristine Pearl Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 20-12-2024
- Paid Up Capital ₹ 2.00 Cr
as on 20-12-2024
- Company Age 9 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 34.00 Cr
as on 20-12-2024
- Revenue 109.00%
(FY 2023)
- Profit 99.67%
(FY 2023)
- Ebitda 62.74%
(FY 2023)
- Net Worth 23.23%
(FY 2023)
- Total Assets 38.00%
(FY 2023)
About Pristine Pearl Pharma
The Corporate was formerly known as Pearl Labs(India) Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company currently has active open charges totaling ₹34.00 Cr.
Mohamedayoob, Mohammedsirajudeen Aashikahmed, and Ummalhaseena serve as directors at the Company.
- CIN/LLPIN
U74110TZ2014PTC021000
- Company No.
021000
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Dec 2014
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Coimbatore
Industry
Company Details
- Location
Coimbatore, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Pristine Pearl Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mohamedayoob  | Director | 29-Dec-2014 | Current |
| Mohammedsirajudeen Aashikahmed | Additional Director | 25-Apr-2018 | Current |
| Ummalhaseena | Additional Director | 25-Apr-2018 | Current |
Financial Performance of Pristine Pearl Pharma.
Pristine Pearl Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 109% increase. The company also saw a substantial improvement in profitability, with a 99.67% increase in profit. The company's net worth Soared by an impressive increase of 23.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pristine Pearl Pharma?
In 2023, Pristine Pearl Pharma had a promoter holding of 23.44% and a public holding of 76.56%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pristine Prints Private LimitedActive 1 year 9 monthsMohamedayoob and Mohammedsirajudeen Aashikahmed are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Apr 2024 | ₹19.00 Cr | Open |
Hdfc Bank Limited Creation Date: 24 Dec 2021 | ₹15.00 Cr | Open |
How Many Employees Work at Pristine Pearl Pharma?
Pristine Pearl Pharma has a workforce of 442 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pristine Pearl Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pristine Pearl Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
